FDAnews Drug Daily Bulletin

DEBIOPHARM AND AURIGENE ENTER INTO AGREEMENT TO IDENTIFY AND DEVELOP SELECTIVE COMPOUNDS FOR IMMUNO-ONCOLOGY TARGETS

June 28, 2006
A A

The Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based discovery services company, signed a research agreement to identify and develop compounds for two innovative immuno-oncology targets.
Pipeline Review